A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
| Autor: | Robert A. Hamilton, AnneMarie Nardolillo, Jay. Watsky, Michael P. Kane, Robert S. Busch |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases type 2 diabetes mellitus Endocrinology Diabetes and Metabolism Patient characteristics lcsh:Diseases of the endocrine glands. Clinical endocrinology Internal medicine Internal Medicine medicine In patient canagliflozin Adverse effect Original Research Canagliflozin lcsh:RC648-665 business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus Invokana Regimen Tolerability SGLT-2 inhibitor Observational study business Biomedical engineering medicine.drug |
| Zdroj: | Clinical Medicine Insights: Endocrinology and Diabetes, Vol 2014, Iss 7, Pp 25-30 (2014) Clinical Medicine Insights: Endocrinology and Diabetes, Vol 7 (2014) Clinical Medicine Insights. Endocrinology and Diabetes |
| ISSN: | 1179-5514 |
| Popis: | Objective To assess the real-world efficacy and safety of the first sodium-glucose cotransporter-2 inhibitor, canagliflozin, in the treatment of patients with type 2 diabetes mellitus (T2DM). Methods This observational study assessed the efficacy and tolerability of canagliflozin in T2DM patients. Primary study outcomes were changes in HbAlC and weight, and percentage of patients reporting adverse effects of therapy. Results The study criteria were met by 111 patient records. Baseline patient characteristics were: average age, 59 ± 9 years; mean duration of T2DM, 11.9 ± 7.3 years; 57.6% of patients were male; 92.8% were Caucasian; baseline BMI, 38.9 ± 11 kg/m2; and mean baseline HbAlC, 7.53 (58.8 mmol/mol) ± 1.08%. HbAlC and weight were significantly reduced by 0.37% and 4.4 kg, respectively. Adverse effects were reported by 21 patients, and 17 (15.3%) discontinued canagliflozin because of adverse reactions. Conclusion Canagliflozin was generally well tolerated and significantly reduced HbAlC levels and body weight in patients with T2DM when added to a regimen of other anti-hyperglycemic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|